Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03487926
Other study ID # 102-2016
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date September 14, 2022
Est. completion date December 31, 2024

Study information

Verified date February 2024
Source Centre for Addiction and Mental Health
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to monitor microglial activation in participants with inflammatory bowel disease (IBD) and investigate the relationship that exists between these patients and their risk of acquiring major depressive episodes (MDE). Patients with both IBD and MDE will be subsequently approached to participate in the study.


Description:

Detailed Description: Participants may undergo up to 3 PET Scans : [18F]FEPPA PET (for TSPO) before and 3 to 6 months later and [11C]SL25.1188 PET (for MAO-B) as well as 1 MRI scan. The primary hypothesis is that : 1. The neuroinflammation (TSPO VT) will be increased in PFC, ACC, and insula regions in those with inflammatory bowel disease (IBD) patients compared to healthy people. 2. The neuroinflammation (TSPO VT) in PFC, ACC, and insula regions will be reduced after treatment for IBD. The Secondary Hypothesis: 1. Elevations in neuroinflammation (TSPO VT) will be similar in those with ulcerative colitis and Crohn's disease. 2. Neuroinflammation (TSPO VT) will be greater in IBD with depression than in depression without IBD. 3. Biologics (TNFalpha antibody treatments), and fecal transplantation will be associated with greater reduction in neuroinflammation in brain than Sulfasalazine/5-Aminosalicylates. 4. MAO-B VT will be elevated in in the PFC, ACC, and insula in IBD compared to healthy controls. There will be no alterations to standard care of patients due to participation in the study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 135
Est. completion date December 31, 2024
Est. primary completion date December 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 65 Years
Eligibility Inclusion Criteria: - Age 18 to 65 - aside from IBD groups and common comorbidities of IBD, otherwise good physical health with no current active medical conditions. - a lifetime diagnosis of IBD verified by medical record, which can include prescription for IBD treatment Exclusion Criteria: - no history of neurological illness, excluding migraine - no use of glucocorticoid antagonists or lithium or medications that bind with affinity higher than 500nM to peripheral benzodiazepine receptors (or TSPO) in the previous two months - no use of herbal remedies in the previous month that would be expected to influence neuroinflammation - non-cigarette smoking - no history of abuse of substances that affect mood and negative urine drug screens for substances of abuse including cotinine (urine drug screen is done at screening and on each PET scan day) - no history of psychotic symptoms - not pregnant based on a negative pregnancy test (for women) - not breastfeeding (for women) - no recent treatment with electroconvulsive therapy or magnetic seizure therapy in the previous 6 months - no coagulation disorders, or anticoagulant medication use - no presence of metal objects or implanted electrical devices in the body that would preclude MRI scanning - no claustrophobia - no self-reported history of fainting from blood withdrawals - size and weight does not exceed capacity of scanner, for which size may vary and weight is 350 lbs - no history of undergoing a number of PET scans that, including the number of PET scans under this protocol, will bring the total to more than 8 PET scans/lifetime, exceeding permissible limit for subjects participating in research set by our centre's guidelines

Study Design


Intervention

Radiation:
[18F]FEPPA
up to 3 PET Scans ([18F]FEPPA PET scans done 3 to 6 months apart, and one [11C]SL2511.88 PET scan) and 1 MRI

Locations

Country Name City State
Canada Centre for Addiction and Mental Health Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
Centre for Addiction and Mental Health McMaster University

Country where clinical trial is conducted

Canada, 

References & Publications (4)

Attwells S, Setiawan E, Wilson AA, Rusjan PM, Mizrahi R, Miler L, Xu C, Richter MA, Kahn A, Kish SJ, Houle S, Ravindran L, Meyer JH. Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder. JAMA Psychiatry. 2017 Aug 1;74(8):833-840. doi: 10.10 — View Citation

Holmes SE, Hinz R, Conen S, Gregory CJ, Matthews JC, Anton-Rodriguez JM, Gerhard A, Talbot PS. Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. — View Citation

Li H, Sagar AP, Keri S. Translocator protein (18kDa TSPO) binding, a marker of microglia, is reduced in major depression during cognitive-behavioral therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Apr 20;83:1-7. doi: 10.1016/j.pnpbp.2017.12.011. — View Citation

Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, Suridjan I, Kennedy JL, Rekkas PV, Houle S, Meyer JH. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary TSPO VT in prefrontal cortex, anterior cingulate cortex, and insula Between group comparison for 3 regions in IBD compared to controls (analysis done concurrently for group effect across 3 regions) within 3 to 4 weeks after initiation of screening
Primary change in TSPO VT in prefrontal cortex, anterior cingulate cortex, and insula before and after 3 to 6 months Change in TSPO VT for three regions (same units for each region) 3 to 6 months
Primary MAO-B VT in prefrontal cortex, anterior cingulate cortex, insula in IBD compared to controls Between group comparison for 3 regions in IBD compared to controls within 3 to 4 weeks after initiation of screening
Secondary TSPO VT in prefrontal cortex, anterior cingulate cortex, insula compared between Crohns disease and ulcerative colitis comparison of TSPO VT in 3 regions between two types of inflammatory bowel disease within 3 to 4 weeks of initiating screening of subjects
Secondary TSPO VT in prefrontal cortex, anterior cingulate cortex, insula compared between IBD with MDE compared to MDE controls Between group comparison for 3 regions in IBD compared to controls within 3 to 4 weeks after initiation of screening
Secondary change in TSPO VT in prefrontal cortex, anterior cingulate cortex, insula compared between naturalistic treatment with sulfasalazine/5-aminosalicylates versus other interventions like biologics or fecal transplantation differential change in TSPO VT across 3 regions before and after 6 months in those receiving naturalistic treatment with sulfasalazine/5-aminosalicylates versus other naturalistic treatments of fecal transplantation or biologics 3 to 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Active, not recruiting NCT04989907 - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Active, not recruiting NCT04990258 - A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Completed NCT06216223 - Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients N/A
Enrolling by invitation NCT06015789 - Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
Recruiting NCT06065995 - StoMakker Mobile Application N/A
Recruiting NCT03282786 - Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease N/A
Recruiting NCT06002074 - SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases N/A
Recruiting NCT04960826 - Study of an Environmental Risk Factor in Crohn's Disease
Recruiting NCT05413941 - Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease N/A
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed NCT00721812 - A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 Phase 1
Recruiting NCT05809999 - IBD Neoplasia Surveillance RCT N/A
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Recruiting NCT04991324 - Cholecalciferol Comedication in IBD - the 5C-study Phase 3
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Not yet recruiting NCT05043818 - A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Completed NCT02874365 - Intestinal Stem Cells Characterization N/A